David Thomas

David covers investment, R&D and alliance deal trends as well as regulatory statistics that impact policy initiatives in Washington. Prior to joining BIO, David spent over a decade in the biotech industry as a biochemist in drug discovery at Amgen, Millennium and Novartis, and later in synthetic biology at the J Craig Venter Institute. David is also a financial analyst specializing in risk-adjusted DCF models and holds the Chartered Financial analyst (CFA) designation.